Christian Griñán Ferré

Dr. Christian Griñán-Ferré

christian.grinan@ub.edu
Pharmacology Unit – Department of Pharmacology, Toxicology and Therapeutic Chemistry
Faculty of Pharmacy and Food Sciences
Av. Joan XXIII, 27-31, building A,
08028 – Barcelona, Catalunya (Spain)
Tel: 934021505; Ext. 21505

ORCID: 0000-0002-5424-9130; https://orcid.org/0000-0002-5424-9130
ResearchGate: https://www.researchgate.net/profile/Christian-Ferre
Webpage: www. neuroepilab.com

The Neuroepilab, led by Prof. Christian Griñán-Ferré, focuses on developing epigenetic-based therapies for central nervous system (CNS) disorders. The group investigates how alterations in chromatin remodeling and RNA methylation (m6A) influence gene expression, synaptic function, and cognitive decline in neurodegenerative and neurodevelopmental diseases, including Alzheimer’s.

A key line of research centers on inhibitors of enzymes such as G9a, with lead compounds already validated in C. elegans and mouse models of Alzheimer’s and other CNS disorders. These candidates are currently progressing toward the preclinical regulatory phase.

With strong expertise in neuropharmacology, bioinformatics, and preclinical model development, the group employs C. elegans as a drug screening tool, a method Dr. Griñán-Ferré refined during his postdoctoral research at Semmelweis University. Neuroepilab is actively involved in CIBERNED and the GENiE network.

Through its research, the group aims to foster scientific innovation, facilitate the translation of discoveries into therapeutic solutions, and contribute to better clinical outcomes for individuals affected by CNS disorders.

Prof. Christian Griñán-Ferré is an Associate Professor at the University of Barcelona since 2023, specializing in neuroepigenetics and drug discovery for central nervous system disorders. He completed his PhD at UB, receiving the Extraordinary Doctorate Award for his work on epigenetic modulation in Alzheimer’s disease. Currently, he leads the Neuroepilab group.

He has published over 100 papers (h-index 26), holds 15 patent applications (two licensed to the start-up Neuraly) and has obtained several innovation grants and industry contracts. He has participated in 25 research projects, supervised six PhD theses and more than ten MSc students, and has over a decade of teaching experience in pharmacology, neuropharmacology, epigenetics, biomedicine, and aging.

Team members

Dr. Aina Bellver Sanchis

Post-doctoral researcher

Dr. Ariadna Boloix Amenós

Innovation project manager

Alba Irisarri Martínez

PhD Student

Núria Pérez Salvador

PhD Student

Past members:
Carmen Fernández Martínez (Post-doctoral researcher, 2025)

Alumni:
M Dolors Puigoriol-Illamola (PhD, 2020)
Foteini Vasilopoulou (PhD, 2021)
Júlia Companys-Alemany (PhD, 2022)

Publications at a glance

Irisarri A, Corral A, Perez-Salvador N, Bellver-Sanchis A, Ribalta-Vilella M, Bentanachs R, Alegret M, Laguna JC, Barroso E, Palomer X, Guerrero A, Ortuño-Sahagún D, Vázquez-Carrera M, Pallàs M, Herrero L, Griñán-Ferré C. FTO Inhibition Mitigates High-fat Diet-Induced Metabolic Disturbances and Cognitive Decline in SAMP8 Mice. Mol Med. 2025 Feb 21;31(1):73. doi: 10.1186/s10020-025-01126-4.
Bellver-Sanchis A, Ribalta-Vilella M, Irisarri A, Gehlot P, Choudhary BS, Jana A, Vyas VK, Banerjee DR, Pallàs M, Guerrero A, Griñán-Ferré C. G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials. Med Res Rev. 2025 Jan 6. doi: 10.1002/med.22096. Online ahead of print. PMID: 39763018.
Bellver-Sanchis A, Geng Q, Navarro G, Ávila-López PA, Companys-Alemany J, Marsal-García L, Larramona-Arcas R, Miró L, Perez-Bosque A, Ortuño-Sahagún D, Banerjee DR, Choudhary BS, Soriano FX, Poulard C, Pallàs M, Du HN, Griñán-Ferré C. G9a Inhibition Promotes Neuroprotection through GMFB Regulation in Alzheimer’s Disease. Aging Dis. 2024 Feb 1;15(1):311-337. doi: 10.14336/AD.2023.0424-2. PMID: 37307824; PMCID: PMC10796087.
Bellver-Sanchis A, Ávila-López PA, Tic I, Valle-García D, Ribalta-Vilella M, Labrador L, Banerjee DR, Guerrero A, Casadesus G, Poulard C, Pallàs M, Griñán-Ferré C. Neuroprotective effects of G9a inhibition through modulation of peroxisome-proliferator activator receptor gamma-dependent pathways by miR-128. Neural Regen Res. 2024 Nov 1;19(11):2532-2542. doi: 10.4103/1673-5374.393102. Epub 2024 Jan 8. PMID: 38526289; PMCID: PMC11090428.
Griñán-Ferré C, Servin-Muñoz IV, Palomera-Ávalos V, Martínez-Fernández C, Companys-Alemany J, Muñoz-Villanova A, Ortuño-Sahagún D, Pallàs M, Bellver-Sanchis A. Changes in Gene Expression Profile with Age in SAMP8: Identifying Transcripts Involved in Cognitive Decline and Sporadic Alzheimer’s Disease. Genes (Basel). 2024 Oct 31;15(11):1411. doi: 10.3390/genes15111411.PMID: 39596610; PMCID: PMC11593728.

2025

Yañez-Esparza A, Corona-Meraz FI, Mireles-Ramírez MA, Reyes-Mata MP, Martínez-Fernández C, Pallàs M, Griñan-Ferré C, Pavón L, Guerrero-García JJ, Ortuño-Sahagún D. Alterations in the miR-145/143 cluster expression in multiple sclerosis patients and their correlation with clinical variables. Mult Scler Relat Disord. 2025. DOI: 10.1016/j.msard.2025.106344.
Jarne-Ferrer J, Sánchez J, Codony S, Schneider M, Müller CE, Sanfeliu C, Franco R, Vazquez S, Griñán-Ferré C, Pallàs M. Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies. ACS Pharmacol Transl Sci. 2025 Jan 29;8(2):533-542. doi: 10.1021/acsptsci.4c00629. eCollection 2025 Feb 14. PMID: 39974649; PMCID: PMC11833725.
Bagán A, López-Ruiz A, Abás S, Ruiz-Cantero MC, Vasilopoulou F, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Muguruza C, Diez-Alarcia R, Callado LF, Entrena JM, Cobos EJ, Pérez B, Morales-García JA, Molins E, De Jonghe S, Daelemans D, Brea J, Val C, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Díaz C, Fernández-Godino R, Genilloud O, Beljkaš M, Oljačić S, Nikolic K, Escolano C. Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates as Imidazoline I2 Receptor Ligands with Anti-Alzheimer and Analgesic Properties. J Med Chem. 2025 Feb 13;68(3):2551-2573. doi: 10.1021/acs.jmedchem.4c01644. Epub 2025 Jan 17. PMID: 39818939; PMCID: PMC11831594.

2024:

Griñán-Ferré C, Bellver-Sanchis A, Guerrero A, Pallàs M. Advancing personalized medicine in neurodegenerative diseases: The role of epigenetics and pharmacoepigenomics in pharmacotherapy. Pharmacol Res. 2024 Jul;205:107247. doi: 10.1016/j.phrs.2024.107247. Epub 2024 Jun 2. PMID: 38834164.
Palomer X, Salvador JM, Griñán-Ferré C, Barroso E, Pallàs M, Vázquez-Carrera M. GADD45A: With or without you. Med Res Rev. 2024 Jul;44(4):1375-1403. doi: 10.1002/med.22015. Epub 2024 Jan 24. PMID: 37994388.
Servín Muñoz IV, Ortuño-Sahagún D, Griñán-Ferré C, Pallàs M, González-Castillo C. Alterations in Proteostasis Mechanisms in Niemann-Pick Type C Disease. Int J Mol Sci. 2024 Mar 29;25(7):3806. doi: 10.3390/ijms25073806. PMID: 38612616; PMCID: PMC11011983.
Ibeas K, Griñán-Ferré C, Del Mar Romero M, Sebastián D, Bastías-Pérez M, Gómez R, Soler-Vázquez MC, Zagmutt S, Pallás M, Castell M, Belsham DD, Mera P, Herrero L, Serra D. Cpt1a silencing in AgRP neurons improves cognitive and physical capacity and promotes healthy aging in male mice. Aging Cell. 2024 Feb;23(2):e14047. doi: 10.1111/acel.14047. Epub 2023 Nov 22. PMID: 37994388; PMCID: PMC10861206.
Sukanya S, Bellver-Sanchis A, Singh Choudhary B, Kumar S, Pérez B, Leandro Martínez Rodríguez A, Brea J, Griñán-Ferré C, Malik R. Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer’s agent. Bioorg Chem. 2024 Dec;153:107811. doi: 10.1016/j.bioorg.2024.107811. Epub 2024 Sep 7. PMID: 39270527.
Toledano-Pinedo M, Porro-Pérez A, Schäker-Hübner L, Romero F, Dong M, Samadi A, Almendros P, Iriepa I, Bautista-Aguilera ÒM, Rodríguez-Fernández MM, Solana-Manrique C, Sanchis I, Mora-Morell A, Rodrìguez AC, Sànchez-Pérez AM, Knez D, Gobec S, Bellver-Sanchis A, Pérez B, Dobrydnev AV, Artetxe-Zurutuza A, Matheu A, Siwek A, Wolak M, Satała G, Bojarski AJ, Doroz-Płonka A, Handzlik J, Godyń J, Więckowska A, Paricio N, Griñán-Ferré C, Hansen FK, Marco-Contelles J. Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases. J Med Chem. 2024 Sep 26;67(18):16533-16555. doi: 10.1021/acs.jmedchem.4c01367. Epub 2024 Sep 10. PMID: 39256214.
Rojas R, Griñán-Ferré C, Castellanos A, Griego E, Martínez M, Navarro-López JD, Jiménez-Díaz L, Rodríguez-Álvarez J, Del Cerro DS, Castillo PE, Pallàs M, Fadó R, Casals N. BETA-Hydroxybutyrate counteracts the deleterious effects of a saturated high-fat diet on synaptic ampa receptors and cognitive performance. bioRxiv [Preprint]. 2024 Jul 22:2024.01.23.576931. doi: 10.1101/2024.01.23.576931. PMID: 39091837.
Griñán-Ferré C, Bellver-Sanchis A, Guerrero A, Pallàs M. Advancing personalized medicine in neurodegenerative diseases: The role of epigenetics and pharmacoepigenomics in pharmacotherapy. Pharmacol Res. 2024 Jul;205:107247. doi: 10.1016/j.phrs.2024.107247. Epub 2024 Jun 2. PMID: 38834164.
Solà-Ginés M, Miró L, Bellver-Sanchis A, Griñán-Ferré C, Pallàs M, Pérez-Bosque A, Moretó M, Pont L, Benavente F, Barbosa J, Rodríguez C, Polo J. Nutritional, molecular, and functional properties of a novel enzymatically hydrolyzed porcine plasma product. PLoS One. 2024 May 10;19(5):e0301504. doi: 10.1371/journal.pone.0301504. eCollection 2024. PMID: 38728303; PMCID: PMC11086891.
Griñán-Ferré C, Jarne-Ferrer J, Bellver-Sanchis A, Ribalta-Vilella M, Barroso E, Salvador JM, Jurado-Aguilar J, Palomer X, Vázquez-Carrera M, Pallàs M. Deletion of Gadd45a Expression in Mice Leads to Cognitive and Synaptic Impairment Associated with Alzheimer’s Disease Hallmarks. Int J Mol Sci. 2024 Feb 23;25(5):2595. doi: 10.3390/ijms25052595. PMID: 38473843; PMCID: PMC10931605.
Griñán-Ferré C, Jarné-Ferrer J, Bellver-Sanchís A, Codony S, Puigoriol-Illamola D, Sanfeliu C, Oh Y, Lee S, Vázquez S, Pallàs M. Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer’s disease therapeutics. CNS Neurosci Ther. 2024 Apr;30(4):e14511. doi: 10.1111/cns.14511. Epub 2023 Oct 31. PMID: 37905690; PMCID: PMC11017401.
Jana A, Naga R, Saha S, Griñán-Ferré C, Banerjee DR. Integration of ligand and structure-based pharmacophore screening for the identification of novel natural leads against Euchromatic histone lysine methyltransferase 2 (EHMT2/G9a). J Biomol Struct Dyn. 2024 Apr;42(7):3535-3562. doi: 10.1080/07391102.2023.2213346. Epub 2023 May 22. PMID: 37216299.

2023:

Bagán A, Abás S, Palà-Pujadas J, Irisarri A, Griñán-Ferré C, Pallàs M, Muneta-Arrate I, Muguruza C, Callado LF, Pérez B, Molins E, Morales-García JÁ, Escolano C. Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I2 receptor ligands. Bioorg Chem. 2023 Oct 24;142:106935. doi: 10.1016/j.bioorg.2023.106935. Online ahead of print. PMID: 39492364.
Jana A, Bellver-Sanchis A, Griñán-Ferré C, Banerjee DR. Repurposing of Raltitrexed as an Effective G9a/EHMT2 Inhibitor and Promising Anti-Alzheimer’s Agent. ACS Med Chem Lett. 2023 Oct 12;14(11):1531-1536. doi: 10.1021/acsmedchemlett.3c00344. eCollection 2023 Nov 9. PMID: 37974951; PMCID: PMC10641905.
Bagán A, Rodriguez-Arévalo S, Taboada-Jara T, Griñán-Ferré C, Pallàs M, Brocos-Mosquera I, Callado LF, Morales-García JA, Pérez B, Diaz C, Fernández-Godino R, Genilloud O, Beljkas M, Oljacic S, Nikolic K, Escolano C. Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease. Pharmaceutics. 2023 Sep 25;15(10):2381. doi: 10.3390/pharmaceutics15102381. PMID: 37896141; PMCID: PMC10610545.
Reyes-Mata MP, Mireles-Ramírez MA, Griñán-Ferré C, Pallàs M, Pavón L, Guerrero-García JJ, Ortuño-Sahagún D. Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA-A Preliminary Study. Int J Mol Sci. 2023 May 22;24(10):9074. doi: 10.3390/ijms24109074. PMID: 37240421; PMCID: PMC10219581.

2022:

Bartra C, Irisarri A, Villoslada A, Corpas R, Aguirre S, García-Lara E, Suñol C, Pallàs M, Griñán-Ferré C, Sanfeliu C. Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer’s Disease Neurodegeneration. Int J Mol Sci. 2022 Dec 2;23(23):15151. doi: 10.3390/ijms232315151. PMID: 36499477; PMCID: PMC9740580.
Companys-Alemany J, Turcu AL, Vázquez S, Pallàs M, Griñán-Ferré C. Glial cell reactivity and oxidative stress prevention in Alzheimer’s disease mice model by an optimized NMDA receptor antagonist. Sci Rep. 2022 Oct 25;12(1):17908. doi: 10.1038/s41598-022-22963-x. PMID: 36284170; PMCID: PMC9596444.
Ortuño-Sahagún D, Enterría-Rosales J, Izquierdo V, Griñán-Ferré C, Pallàs M, González-Castillo C. The Role of the miR-17-92 Cluster in Autophagy and
Atherosclerosis Supports Its Link to Lysosomal Storage Diseases. 2022 Sep 26;11(19):2991. doi: 10.3390/cells11192991. PMID: 36230953; PMCID: PMC9564236.
Codony S, Entrena JM, Calvó-Tusell C, Jora B, González-Cano R, Osuna S, Corpas R, Morisseau C, Pérez B, Barniol-Xicota M, Griñán-Ferré C, Pérez C,
Rodríguez-Franco MI, Martínez AL, Loza MI, Pallàs M, Verhelst SHL, Sanfeliu C, Feixas F, Hammock BD, Brea J, Cobos EJ, Vázquez S. Synthesis, In Vitro
Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. J Med Chem. 2022 Oct 27;65(20):13660-13680. doi: 10.1021/acs.jmedchem.2c00515. Epub 2022 Oct 12. PMID: 36222708; PMCID: PMC9620236.
Companys-Alemany J, Roig-Soriano J, Turcu AL, Chillón M, Vázquez S, Pallàs M, Griñán-Ferré C. Optimized N-methyl-D-aspartate receptor antagonist exhibits hippocampal proneurogenic effects in aged senescence-accelerated mouse prone 8 mice. 2022 Oct 5;33(14):623-628. doi: 10.1097/WNR.0000000000001825. Epub 2022 Aug 20. PMID: 36062512.
Vasilopoulou F, Bellver-Sanchis A, Companys-Alemany J, Jarne-Ferrer J, Irisarri A, Palomera-Ávalos V, Gonzalez-Castillo C, Ortuño-Sahagún D, Sanfeliu C, Pallàs M, Griñán-Ferré C. Cognitive Decline and BPSD Are Concomitant with Autophagic and Synaptic Deficits Associated with G9a Alterations in Aged SAMP8 Mice. 2022 Aug 21;11(16):2603. doi: 10.3390/cells11162603. PMID: 36010679; PMCID: PMC9406492.
Jarne-Ferrer J, Griñán-Ferré C, Bellver-Sanchis A, Vázquez S, Muñoz-Torrero D, Pallàs M. A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer’s Disease Mice Models. Pharmaceuticals (Basel). 2022 Jul 22;15(8):908. doi: 10.3390/ph15080908. PMID: 35893732; PMCID: PMC9394299.
Sánchez-Melgar A, Izquierdo-Ramírez PJ, Griñán-Ferré C, Pallàs M, Martín M, Albasanz JL. Neuroprotective Effects of Resveratrol by Modifying Cholesterol Metabolism and Aβ Processing in SAMP8 Mice. Int J Mol Sci. 2022 Jul 8;23(14):7580. doi: 10.3390/ijms23147580. PMID: 35886936; PMCID: PMC9324102.
Companys-Alemany J, Turcu AL, Schneider M, Müller CE, Vázquez S, Griñán-Ferré C, Pallàs M. NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice. Cell Mol Life Sci. 2022 Jul 9;79(8):408. doi: 10.1007/s00018-022-04438-4. PMID: 35810220; PMCID: PMC9271115.
Rosell-Cardona C, Amat C, Griñán-Ferré C, Polo J, Pallàs M, Pérez-Bosque A, Moretó M, Miró L. The Neuroprotective Effects of Spray-Dried Porcine Plasma Supplementation Involve the Microbiota-Gut-Brain Axis. 2022 May 26;14(11):2211. doi: 10.3390/nu14112211. PMID: 35684013; PMCID: PMC9183112.
Bagán A, Morales-García JA, Griñán-Ferré C, Díaz C, Pérez Del Palacio J, Ramos MC, Vicente F, Pérez B, Brea J, Loza MI, Pallàs M, Escolano C. Insights into the Pharmacokinetics and In Vitro Cell-Based Studies of the Imidazoline I2 Receptor Ligand B06. Int J Mol Sci. 2022 May 12;23(10):5408. Doi:10.3390/ijms23105408. PMID: 35628219; PMCID: PMC9141032.
Turcu AL, Companys-Alemany J, Phillips MB, Patel DS, Griñán-Ferré C, Loza MI, Brea JM, Pérez B, Soto D, Sureda FX, Kurnikova MG, Johnson JW, Pallàs M, Vázquez S. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer’s disease. Eur J Med Chem. 2022 Jun 5;236:114354. doi: 10.1016/j.ejmech.2022.114354. Epub 2022 Apr 8. PMID: 35453065; PMCID: PMC9106868.
Bellver-Sanchis A, Singh Choudhary B, Companys-Alemany J, Sukanya, Ávila- López PA, Martínez Rodríguez AL, Brea Floriani JM, Malik R, Pallàs M, Pérez B, Griñán-Ferré C. Structure-Based Virtual Screening and in vitro and in vivo Analyses Revealed Potent Methyltransferase G9a Inhibitors as Prospective Anti-Alzheimer’s Agents. ChemMedChem. 2022 Jul 5;17(13):e202200002. doi: 10.1002/cmdc.202200002. Epub 2022 May 19. PMID: 35413149; PMCID: PMC9401600.
Codony S, Pont C, Griñán-Ferré C, Di Pede-Mattatelli A, Calvó-Tusell C, Feixas F, Osuna S, Jarné-Ferrer J, Naldi M, Bartolini M, Loza MI, Brea J, Pérez B, Bartra C, Sanfeliu C, Juárez-Jiménez J, Morisseau C, Hammock BD, Pallàs M, Vázquez S, Muñoz-Torrero D. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer’s Disease. J Med Chem. 2022 Mar 24;65(6):4909-4925. doi: 10.1021/acs.jmedchem.1c02150. Epub 2022 Mar 10. PMID: 35271276; PMCID: PMC8958510.
Roig-Soriano J, Griñán-Ferré C, Espinosa-Parrilla JF, Abraham CR, Bosch A, Pallàs M, Chillón M. AAV-mediated expression of secreted and transmembrane αKlotho isoforms rescues relevant aging hallmarks in senescent SAMP8 mice. Aging Cell. 2022 Apr;21(4):e13581. doi: 10.1111/acel.13581. Epub 2022 Mar 10. PMID: 35274439; PMCID: PMC9009104.

2021:

Bellver-Sanchis A, Pallàs M, Griñán-Ferré C. The Contribution of Epigenetic Inheritance Processes on Age-Related Cognitive Decline and Alzheimer’s Disease. 2021 Jun 18;5(2):15. doi: 10.3390/epigenomes5020015. PMID: 34968302; PMCID: PMC8594669.
Rosell-Cardona C, Griñan-Ferré C, Pérez-Bosque A, Polo J, Pallàs M, Amat C, Moretó M, Miró L. Reply to Nifli, A.-P. Comment on «Rosell-Cardona et al.
Dietary Spray-Dried Porcine Plasma Reduces Neuropathological Alzheimer’s Disease Hallmarks in SAMP8 Mice. Nutrients 2021, 13, 2369″. Nutrients. 2021 Nov 13;13(11):4065. doi: 10.3390/nu13114065. PMID: 34836320; PMCID: PMC8625036.
Puigoriol-Illamola D, Companys-Alemany J, McGuire K, Homer NZM, Leiva R, Vázquez S, Mole DJ, Griñán-Ferré C, Pallàs M. Inhibition of 11β-HSD1 Ameliorates Cognition and Molecular Detrimental Changes after Chronic Mild Stress in SAMP8 Mice. Pharmaceuticals (Basel). 2021 Oct 13;14(10):1040. doi: 10.3390/ph14101040. PMID: 34681264; PMCID: PMC8540242.
Roglans N, Baena M, Sangüesa G, Velázquez AM, Griñán-Ferré C, Pallàs M, Sánchez RM, Alegret M, Laguna JC. Chronic liquid fructose supplementation does not cause liver tumorigenesis but elicits clear sex differences in the metabolic response in Sprague-Dawley rats. Food Nutr Res. 2021 Sep 22;65. doi: 10.29219/fnr.v65.7670. PMID: 34650394; PMCID: PMC8494264.
Vasilopoulou F, Escolano C, Pallàs M, Griñán-Ferré C. Microarray Analysis Revealed Inflammatory Transcriptomic Changes after LSL60101 Treatment in 5XFAD Mice Model. Genes (Basel). 2021 Aug 26;12(9):1315. doi: 10.3390/genes12091315. PMID: 34573297; PMCID: PMC8468036.
Izquierdo V, Palomera-Ávalos V, Pallàs M, Griñán-Ferré C. Resveratrol Supplementation Attenuates Cognitive and Molecular Alterations under Maternal High-Fat Diet Intake: Epigenetic Inheritance over Generations. Int. J. Mol. Sci. 2021, 22, 1453. Int J Mol Sci. 2021Aug 25;22(17):9155. doi: 10.3390/ijms22179155. Erratum for: Int J Mol Sci. 2021Feb 01;22(3): PMID: 34502568; PMCID: PMC8430595.
Pont C, Ginex T, Griñán-Ferré C, Scheiner M, Mattellone A, Martínez N, Arce EM, Soriano-Fernández Y, Naldi M, De Simone A, Barenys M, Gómez-Catalán J, Pérez B, Sabate R, Andrisano V, Loza MI, Brea J, Bartolini M, Bolognesi ML, Decker M, Pallàs M, Luque FJ, Muñoz-Torrero D. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. Eur J Med Chem. 2021 Dec 5;225:113779. doi: 10.1016/j.ejmech.2021.113779. Epub 2021 Aug 16: PMID: 34418785.
Griñán-Ferré C, Bellver-Sanchis A, Olivares-Martín M, Bañuelos-Hortigüela O, Pallàs M. Synergistic Neuroprotective Effects of a Natural Product Mixture against AD Hallmarks and Cognitive Decline in Caenorhabditis elegans and an SAMP8 Mice Model. 2021 Jul 14;13(7):2411. doi: 10.3390/nu13072411. PMID: 34371921; PMCID: PMC8308558.
Rosell-Cardona C, Griñan-Ferré C, Pérez-Bosque A, Polo J, Pallàs M, Amat C, Moretó M, Miró L. Dietary Spray-Dried Porcine Plasma Reduces Neuropathological Alzheimer’s Disease Hallmarks in SAMP8 Mice. 2021 Jul 10;13(7):2369.doi: 10.3390/nu13072369. PMID: 34371878; PMCID: PMC8308893.
Pawar S, Bellver-Sanchis A, Griñán-Ferré C. RNA-seq and miRNA-seq data from pharmacological inhibition of the G9a/GLP histone methyltransferase complex with UNC0642 in SAMP8 mice. Data Brief. 2021 May 2;36:107114. doi:10.1016/j.dib.2021.107114. PMID: 34307805; PMCID: PMC8257974.
Rodriguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Pallàs M, Brocos-Mosquera I, Callado LF, Loza MI, Martínez AL, Brea J, Pérez B, Molins E, De Jonghe S, Daelemans D, Radan M, Djikic T, Nikolic K, Hernández-Hernández E, García-Fuster MJ, García-Sevilla JA, Escolano C. Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer’s disease. Eur J Med Chem. 2021 Oct 15;222:113540. doi: 10.1016/j.ejmech.2021.113540. Epub 2021 May 20. PMID: 34118720.
Codony S, Calvó-Tusell C, Valverde E, Osuna S, Morisseau C, Loza MI, Brea J, Pérez C, Rodríguez-Franco MI, Pizarro-Delgado J, Corpas R, Griñán-Ferré C, Pallàs M, Sanfeliu C, Vázquez-Carrera M, Hammock BD, Feixas F, Vázquez S. From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. J Med Chem. 2021 May 13;64(9):5429-5446. doi: 10.1021/acs.jmedchem.0c01601. Epub 2021 May 4. PMID: 33945278; PMCID: PMC8634379.
Vasilopoulou F, Rodríguez-Arévalo S, Bagán A, Escolano C, Griñán-Ferré C, Pallàs M. Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer’s disease mouse model: a comparative study with donepezil. Br J Pharmacol. 2021 Aug;178(15):3017-3033. doi: 10.1111/bph.15478.Epub 2021 May 24. PMID: 33817786.
Griñán-Ferré C, Companys-Alemany J, Jarné-Ferrer J, Codony S, González- Castillo C, Ortuño-Sahagún D, Vilageliu L, Grinberg D, Vázquez S, Pallàs M.
Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease. Int J Mol Sci. 2021 Mar 26;22(7):3409. doi: 10.3390/ijms22073409. PMID: 33810307; PMCID: PMC8036710.
Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, Corpas R, Roig-Soriano J, Chillón M, Andres-Lacueva C, Somogyvári M, Sőti C, Sanfeliu C, Pallàs M. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: From antioxidant to epigenetic therapy. Ageing. Res Rev. 2021 May;67:101271. doi: 10.1016/j.arr.2021.101271. Epub 2021 Feb 8. PMID: 33571701.
Izquierdo V, Palomera-Ávalos V, Pallàs M, Griñán-Ferré C. Resveratrol Supplementation Attenuates Cognitive and Molecular Alterations under Maternal High-Fat Diet Intake: Epigenetic Inheritance over Generations. Int J Mol Sci. 2021 Feb 1;22(3):1453. doi: 10.3390/ijms22031453. Erratum in: Int J Mol Sci. 2021 Aug 25;22(17): PMID: 33535619; PMCID: PMC7867164.
Sarroca S, Gatius A, Rodríguez-Farré E, Vilchez D, Pallàs M, Griñán-Ferré C, Sanfeliu C, Corpas R. Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer’s disease via modulation of proteolytic J Nutr Biochem. 2021 Mar;89:108569. doi: 10.1016/j.jnutbio.2020.108569. Epub 2020 Dec 13. PMID: 33321185.
Vasilopoulou F, Griñán-Ferré C, Rodríguez-Arévalo S, Bagán A, Abás S, Escolano C, Pallàs M. I2 imidazoline receptor modulation protects aged SAMP8 mice against cognitive decline by suppressing the calcineurin Geroscience. 2021 Apr;43(2):965-983. doi: 10.1007/s11357-020-00281-2. Epub 2020 Oct 31. PMID: 33128688; PMCID: PMC8110656.
Puigoriol-Illamola D, Vázquez S, Griñán-Ferré C, Pallàs M. Inhibition of 11β-HSD1, a key enzyme in stress management, improves cognition by RL-118 drug treatment. Neurosci Chron. 2021 Jan 1;2(1):4-8. Available from: http://hdl.handle.net/2445/174524.
Puigoriol-Illamola D, Griñán-Ferré C, Roglans N, Carbó M, Vázquez-Carrera M, Alegret M, Pallàs M. Utilización de casos clínicos en farmacología para mejorar las habilidades y actitudes en el consejo farmacéutico del estudiante de Farmacia. Act Farmacol Ter. 2021 Oct 18;19(3):193-199. Available from: http://hdl.handle.net/2445/184149.
Escolano C, Abás S, Rodríguez-Arévalo S, Bagan A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Callado LF, Pérez B, Pérez-Lozano P, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Díaz C, Pérez J, Ramos C, Vicente F, Molins E, Pallàs M. A bicyclic α iminophosphonate improves cognitive decline in 5xFAD murine model of neurodegeneration. FASEB J. 2021 Jun 22;35(S1):04974. doi: 10.1096/fasebj.2021.35.S1.04974. Available from: http://hdl.handle.net/2445/178883.

2020:

Abás S, Rodríguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Pérez B, Molins E, Luque FJ, Pérez-Lozano P, de Jonghe S, Daelemans D, Naesens L, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Pallàs M, Callado LF, Escolano C. Correction to Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease. J Med Chem. 2020 Sep 24;63(18):10529. doi: 10.1021/acs.jmedchem.0c01324. Epub 2020 Sep 14. Erratum for: J Med Chem. 2020 Apr 9;63(7):3610-3633. PMID: 32924503.
Sánchez-Melgar A, Albasanz JL, Griñán-Ferré C, Pallàs M, Martín M. Adenosine and Metabotropic Glutamate Receptors Are Present in Blood Serum and Exosomes from SAMP8 Mice: Modulation by Aging and Resveratrol. 2020 Jul 7;9(7):1628. doi: 10.3390/cells9071628. PMID: 32645849; PMCID: PMC7407497.
Griñán-Ferré C, Codony S, Pujol E, Yang J, Leiva R, Escolano C, Puigoriol- Illamola D, Companys-Alemany J, Corpas R, Sanfeliu C, Pérez B, Loza MI, Brea J, Morisseau C, Hammock BD, Vázquez S, Pallàs M, Galdeano C. Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease. Neurotherapeutics. 2020 Oct;17(4):1825-1835. Doi: 10.1007/s13311-020-00854-1. PMID: 32488482; PMCID: PMC7851240.
Maes T, Mascaró C, Rotllant D, Lufino MMP, Estiarte A, Guibourt N, Cavalcanti F, Griñan-Ferré C, Pallàs M, Nadal R, Armario A, Ferrer I, Ortega A, Valls N, Fyfe M, Martinell M, Castro Palomino JC, Buesa Arjol C. Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. PLoS One. 2020 May 29;15(5):e0233468. doi: 10.1371/journal.pone.0233468. PMID: 32469975; PMCID: PMC7259601.
Vasilopoulou F, Bagan A, Rodriguez-Arevalo S, Escolano C, Griñán-Ferré C, Pallàs M. Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I2-Imidazoline Receptor Ligand MCR5. 2020 May 23;12(5):475. doi: 10.3390/pharmaceutics12050475. PMID: 32456135; PMCID: PMC7285228.
Pallàs M, Vázquez S, Sanfeliu C, Galdeano C, Griñán-Ferré C. Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy. 2020 May 1;10(5):703. doi: 10.3390/biom10050703. PMID: 32369955; PMCID: PMC7277900.
Companys-Alemany J, Turcu AL, Bellver-Sanchis A, Loza MI, Brea JM, Canudas AM, Leiva R, Vázquez S, Pallàs M, Griñán-Ferré C. A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice. 2020 Mar 22;12(3):284. doi: 10.3390/pharmaceutics12030284. PMID: 32235699; PMCID: PMC7151078.
Abás S, Rodríguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Pérez B, Molins E, Luque FJ, Pérez-Lozano P, de Jonghe S, Daelemans D, Naesens L, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Pallàs M, Callado LF, Escolano C. Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer’s Disease. J Med Chem. 2020 Apr 9;63(7):3610-3633. doi: 10.1021/acs.jmedchem.9b02080. Epub 2020 Mar 19. Erratum in: J Med Chem. 2020 Sep 24;63(18):10529. PMID: 32150414.
Puigoriol-Illamola D, Martínez-Damas M, Griñán-Ferré C, Pallàs M. Chronic Mild Stress Modified Epigenetic Mechanisms Leading to Accelerated Senescence and Impaired Cognitive Performance in Mice. Int J Mol Sci. 2020 Feb 10;21(3):1154. doi: 10.3390/ijms21031154. PMID: 32050516; PMCID: PMC7037343.
Garcia-Just A, Miró L, Pérez-Bosque A, Amat C, Polo J, Pallàs M, Griñán-Ferré C, Moretó M. Dietary Spray-Dried Porcine Plasma Prevents Cognitive Decline in Senescent Mice and Reduces Neuroinflammation and Oxidative Stress. J Nutr. 2020 Feb 1;150(2):303-311. doi: 10.1093/jn/nxz239. PMID: 31562503.
Puigoriol-Illamola D, Leiva R, Vázquez-Carrera M, Vázquez S, Griñán-Ferré C, Pallàs M. 11β-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress. Mol Neurobiol. 2020 Jan;57(1):551-565. doi:1007/s12035-019-01708-4. Epub 2019 Aug 9. PMID: 31399953.

2019:

Griñán-Ferré C, Vasilopoulou F, Abás S, Rodríguez-Arévalo S, Bagán A, Sureda FX, Pérez B, Callado LF, García-Sevilla JA, García-Fuster MJ, Escolano C, Pallàs M. Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice. 2019 Apr;16(2):416-431. doi: 10.1007/s13311-018-00681-5. PMID: 30460457; PMCID: PMC6554384.
Corpas R, Solana E, De la Rosa A, Sarroca S, Griñán-Ferré C, Oriol M, Corbella E, Rodríguez-Farré E, Vina J, Pallàs M, Bartrés-Faz D, Gomez-Cabrera MC, Sanfeliu C. Peripheral Maintenance of the Axis SIRT1-SIRT3 at Youth Level May Contribute to Brain Resilience in Middle-Aged Amateur Rugby Players. Front Aging Neurosci. 2019 Dec 17;11:352. doi: 10.3389/fnagi.2019.00352. PMID: 31956305; PMCID: PMC6951402.
Griñán-Ferré C, Marsal-García L, Bellver-Sanchis A, Kondengaden SM, Turga RC, Vázquez S, Pallàs M. Pharmacological inhibition of G9a/GLP restores cognition and reduces oxidative stress, neuroinflammation and β-Amyloid plaques in an early-onset Alzheimer’s disease mouse model. Aging (Albany NY). 2019 Dec 4;11(23):11591-11608. doi: 10.18632/aging.102558. Epub 2019 Dec 4. PMID: 31804189; PMCID: PMC6932909.
Izquierdo V, Palomera-Ávalos V, López-Ruiz S, Canudas AM, Pallàs M, Griñán- Ferré C. Maternal Resveratrol Supplementation Prevents Cognitive Decline in Senescent Mice Offspring. Int J Mol Sci. 2019 Mar 6;20(5):1134. doi: 10.3390/ijms20051134. PMID: 30845644; PMCID: PMC6429303.
Corpas R, Griñán-Ferré C, Rodríguez-Farré E, Pallàs M, Sanfeliu C. Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement. Mol Neurobiol. 2019 Feb;56(2):1502-1516. doi: 10.1007/s12035-018-1157-y. Epub 2018 Jun 13. PMID: 29948950.
Escolano C, Griñan-Ferre C, Vasilopoulou F, Abàs S, Rodríguez-Arévalo S, Bagan A, Pérez B. Callado L. F, García-Sevilla J. A, García-Fuster M. J, Pallàs M, Brea J, Loza MI. A New Family of Imidazoline I2 Receptor Ligands Improves Behavior and Cognition in SAMP8 Mice. The FASEB Journal. 2019 April 5; 33 (S1): 806.19-806.19. https://doi.org/10.1096/fasebj.2019.33.1_supplement.806.19.
Bagán A, Abás S, Rodríguez-Arévalo S, Rodríguez-Arévalo G, Vasilopoulou F, Griñán-Ferré C, Pallàs M, Pérez-Lozano P, Radan M, Djikic T, Nikolic K, Escolano C. 2-(imidazolin-4-yl)phosphonates: Green chemistry and biology walk together. MDPI Proceedings. 2019 Sep;22:97. doi: 10.3390/proceedings2019022097.

2018:

Puigoriol-Illamola D, Griñán-Ferré C, Vasilopoulou F, Leiva R, Vázquez S, Pallàs M. 11β-HSD1 Inhibition by RL-118 Promotes Autophagy and Correlates with Reduced Oxidative Stress and Inflammation, Enhancing Cognitive Performance in SAMP8 Mouse Model. Mol Neurobiol. 2018 Dec;55(12):8904-8915. doi: 10.1007/s12035-018-1026-8. Epub 2018 Apr 2. PMID: 29611102.
Griñán-Ferré C, Corpas R, Puigoriol-Illamola D, Palomera-Ávalos V, Sanfeliu C, Pallàs M. Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model. J Alzheimers Dis. 2018;62(3):943-963. doi: 10.3233/JAD-170664. PMID: 29562529; PMCID: PMC5870033.
Palomera-Ávalos,V, Griñán-Ferré C, Izquierdo, V, Camins, A, Sanfeliu, C, Canudas, A.M, Pallàs,M. Resveratrol modulates response against acute inflammatory stimuli in aged mouse brain. Exp Gerontol. 2018 Feb:102:3-11. doi: 10.1016/j.exger.2017.11.014. PMID: 29174969.
Corpas R, Griñán-Ferré C, Palomera-Ávalos V, Porquet D, García de Frutos P, Franciscato Cozzolino SM, Rodríguez-Farré E, Pallàs M, Sanfeliu C, Cardoso BR. Melatonin induces mechanisms of brain resilience against neurodegeneration. J Pineal Res. 2018 Nov;65(4):e12515. doi: 10.1111/jpi.12515. Epub 2018 Jul 4. PMID: 29907977.
Sangüesa G, Cascales M, Griñán C, Sánchez RM, Roglans N, Pallàs M, Laguna JC, Alegret M. Impairment of Novel Object Recognition Memory and Brain Insulin Signaling in Fructose- but Not Glucose-Drinking Female Rats. Mol Neurobiol. 2018 Aug;55(8):6984-6999. doi: 10.1007/s12035-017-0863-1. PMID: 29372547.
Cosín-Tomás M, Álvarez-López MJ, Companys-Alemany J, Kaliman P, González-Castillo C, Ortuño-Sahagún D, Pallàs M, Griñán-Ferré C. Temporal Integrative Analysis of mRNA and microRNAs Expression Profiles and Epigenetic Alterations in Female SAMP8, a Model of Age-Related Cognitive Decline. Front Genet. 2018 Dec 11;9:596. doi: 10.3389/fgene.2018.00596. PMID: 30619445; PMCID: PMC6297390.
Escolano C, Abàs S, Rodríguez-Arévalo S, Bagan A, Pallàs M, Griñan-Ferre C, Vasilopoulou F, Callado L.F, García-Sevilla A, García-Fuster M. J, Sureda F. X, Pérez G. Novel Imidazoline I2 Receptor Ligands for Alzheimer’s Disease. The FASEB Journal. 2018 April. 32: 552.1. Doi: 10.1096/fasebj.2018.32.1_supplement.552.1.
Griñán-Ferré C, Izquierdo V, Otero E, Puigoriol-Illamola D, Corpas R, Sanfeliu C, Ortuño-Sahagún D, Pallàs M. Environmental Enrichment Improves Cognitive Deficits, AD Hallmarks and Epigenetic Alterations Presented in 5xFAD Mouse Model. Front Cell Neurosci. 2018 Aug 15;12:224. doi:3389/fncel.2018.00224. PMID: 30158856; PMCID: PMC6104164.

2017:

Palomera-Avalos, V, Griñán-Ferré C, Puigoriol-Ilamola, D, Camins, A, Sanfeliu, C, Canudas, AM, Pallàs, M. Resveratrol Protects SAMP8 Brain Under Metabolic Stress: Focus on Mitochondrial Function and Wnt Pathway Molecular Neurobiolog. Mol Neurobiol. 2017 Apr;54(3):1661-1676. doi: 10.1007/s12035-016-9770-0. PMID: 26873850.
Palomera-Ávalos V, Griñán-Ferré C, Izquierdo V, Camins A, Sanfeliu C, Pallàs. Metabolic Stress Induces Cognitive Disturbances and Inflammation in Aged Mice: Protective Role of Resveratrol. Rejuvenation Res. 2017 Jun; 20(3):202-217.doi: 10.1089/rej.2016.1885. Epub 2017 Jan 25. PMID: 27998210.
Leiva R, Griñan-Ferré C, Seira C, Valverde E, McBride A, Binnie M, Pérez B, Luque FJ, Pallàs M, Bidon-Chanal A, Webster SP, Vázquez S. Design, synthesis and in vivo study of novel pyrrolidine-based 11β-HSD1 inhibitors for age-related cognitive dysfunction. Eur J Med Chem. 2017 Oct 20;139:412-428. doi:10.1016/j.ejmech.2017.08.003. Epub 2017 Aug 4. PMID: 28818766.
Alegret M, Sangüesa G, Cascales M, Griñán C, Sánchez RM, Roglans N, Pallàs M, Laguna JC. Impairment of novel object recognition learning and brain insulin signaling in fructose-, but not glucose-drinking, female rats. Atherosclerosis. 2017 July. 263: E268. DOI: 10.1016/j.atherosclerosis.2017.06.865.
Palomera-Avalos V, Griñán-Ferré C, Pallàs, M. 2017. El resveratrol previene el deterioro cerebral propio del envejecimiento. Prensa Científica.
Grinan-Ferre C, Abas S, Vasilopoulou F, Erdozain A. M, Keller B, Rodriguez-Arevalo S, Callado L. F, Garcia-Sevilla J. A, Escolano C, Pallas M. Neuroprotective effect of novel imidazoline i-2 receptor ligands in the senescence accelerated mouse prone 8 (SAMP8). Basic & Clinical Pharmacology & Toxicology. 2017. 121. 33. 1742-7835, 1742-7843.

2016:

Griñan-Ferré C, Palomera-Ávalos V, Puigoriol-Illamola D, Camins A, Porquet D, Plá V, Aguado F, Pallàs M. Behaviour and cognitive changes correlated with
hippocampal neuroinflammaging and neuronal markers in female SAMP8, a model of accelerated senescence. Exp Gerontol. 2016 Jul;80:57-69. doi:
1016/j.exger.2016.03.014. Epub 2016 Apr 17. PMID: 27094468.
Griñán-Ferré C, Sarroca S, Ivanova A, Puigoriol-Illamola D, Aguado F, Camins A, Sanfeliu C, Pallàs M. Epigenetic mechanisms underlying cognitive impairment and Alzheimer disease hallmarks in 5XFAD mice. Aging (Albany NY). 2016 Apr;8(4):664-84. doi: 10.18632/aging.100906. PMID: 27013617; PMCID: PMC4925821.
Griñan-Ferré C, Pérez-Cáceres D, Gutiérrez-Zetina SM, Camins A, Palomera- Avalos V, Ortuño-Sahagún D, Rodrigo MT, Pallàs M. Environmental Enrichment Improves Behavior, Cognition, and Brain Functional Markers in Young Senescence-Accelerated Prone Mice (SAMP8). Mol Neurobiol. 2016 May;53(4):2435-50. doi: 10.1007/s12035-015-9210-6. Epub 2015 May 27. PMID: 26014386.

2015:

Griñan-Ferré C, Puigoriol-Illamola D, Palomera-Ávalos V, Pérez-Cáceres D, Companys-Alemany J, Camins A, Ortuño-Sahagún D, Rodrigo MT, Pallàs M. Environmental Enrichment Modified Epigenetic Mechanisms in SAMP8 Mouse Hippocampus by Reducing Oxidative Stress and Inflammaging and Achieving Neuroprotection. Front Aging Neurosci. 2016 Oct 18;8:241. doi:3389/fnagi.2016.00241. PMID: 27803663; PMCID: PMC5067530.
Porquet D, Andrés-Benito P, Griñán-Ferré C, Camins A, Ferrer I, Canudas AM, Del Vall, J, Pallàs M. Amyloid and tau pathology of familial Alzheimer’s disease APP/PS1 mouse model in a senescence phenotype background (SAMP8). Age (Dordr). 2015 Feb;37(1):9747. doi: 10.1007/s11357-015-9747-3. PMID: 25663420.
Buesa C, Mascaró C, Rotllant D, Griñán-Ferré C, Pallàs M; Maes, T. The dual lsd1/maob inhibitor ory2001 prevents the development of the memory deficit in samp8 mice through induction of neuronal plasticity and reduction of neuroinflammation. Alzheimer’s & Dementia. 2015 July; 11(7):P905. Doi: 10.1016/j.jalz.2015.08.146.

2014:

Sanchez-Roige S, Lalanza JF, Alvarez-López MJ, Cosín-Tomás M, Griñan-Ferré C, Pallàs M, Kaliman P, Escorihuela RM. Long-term wheel running changes on sensorimotor activity and skeletal muscle in male and female mice of accelerated senescence. Age (Dordr). 2014;36(5):9697. doi: 10.1007/s11357-014-9697-1. Epub 2014 Aug 17. PMID: 25129573; PMCID: PMC4159468.
Porquet D, Griñán-Ferré C, Ferrer I, Camins A, Sanfeliu C, Del Valle J, Pallàs M. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer’s disease. J Alzheimers Dis. 2014;42(4):1209-20. doi: 10.3233/JAD-140444. PMID: 25024312.

Book chapters:

Griñán-Ferré C, Izquierdo V, Pallàs M. Dietary antioxidants, epigenetics, and brain aging: a focus on resveratrol. Oxidative Stress and Dietary Antioxidants in Neurological Diseases. 2020. Academic Press, Elsevier. ISBN 978-0-12-817780-8.

Other publications:

Palomera-Avalos V, Griñán-Ferré C, Pallàs M. El resveratrol previene el deterioro cerebral propio del envejecimiento. Prensa Científica. 2017. (Spain). Identifier: 547966.
Griñán-Ferré C, Izquierdo V, Pallàs M. Dietary antioxidants, epigenetics, and brain aging: a focus on resveratrol. In: Oxidative Stress and Dietary Antioxidants in Neurological Diseases. Academic Press, Elsevier; 2020. p. 343-357. ISBN: 978-0-12-817780-8. Available from: https://www.sciencedirect.com/book/9780128177808/oxidative-stress-and-dietary-antioxidants-in-neurologicaldiseases.

Selected Projects

Preclinical development of a first-in-class treatment for autism spectrum disorder (CI25-10446). CaixaImpulse Innovation 2025. PI: Mercè Pallàs Lliberia. (Universitat de Barcelona). 16/09/2025- 15/09/2027. Funds: 50.000 €.

Pioneering a first-in-class epigenetic therapy through RNA modulation for Alzheimer’s disease (2025 PROD 00007). Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). PI: Christian Griñán Ferré. (Universitat de Barcelona). 16/09/2025- 15/03/2027. Funds: 150.000 €.

Preclinical development of a first-in-class treatment for autism spectrum disorder (2025 PROD 00018). Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). PI: Christian Griñán Ferré. (Universitat de Barcelona). 16/09/2025- 15/03/2027. Funds: 150.000 €.

FLAVIUS THERAPEUTICS: Pioneering epigenetic precision medicine to fight CNS conditions (2024 INNOV 00044). Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). Nº 600448. PI: Christian Griñán Ferré. (Universitat de Barcelona). 07/01/2025- 06/07/2026. Funds: 84.000 €.

Validation of the G9a/GSK-3B dual inhibition as a new therapeutic strategy for cognitive decline and Alzheimers disease. Ministerio de Ciencia e Innovación (MICINN). PID2022-139016OA-I00. PI: Griñán Ferré, Christian. 01/09/2023-31/08/2026. Funds: 162.500 €.

Lead optimization of selective G9a inhibitors family for Alzheimer’s disease treatment (2023 PROD 00092). Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). Nº 600404. PI: Christian Griñán Ferré. (Universitat de Barcelona). 01/02/2024- 31/07/2025. Funds: 149.825,25 €.

Optimization of new FTO inhibitors family for main CNS conditions: hit to lead (2023 LLAV 00007). Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). Nº 600399. PI: Christian Griñán Ferré. (Universitat de Barcelona). 01/02/2024-31/07/2024. Funds: 20.000 €.

Optimization of new G9a/HDAC6 dual inhibitors family for Alzheimer’s disease and other CNS conditions: from hit to lead (2023 LLAV 00005). Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). Nº 600406. PI: Christian Griñán Ferré. (Universitat de Barcelona). 01/02/2024-31/07/2024. Funds: 20.000 €.

Device for predicting neurodevelopment outcomes at age two based on AI applied to neonatal EEG recordings to speech. F2I-MiR-2023-001. Fundació Bosch i Gimpera de la Universitat de Barcelona. PI: Griñán Ferré, Christian. 30/01/2024-29/05/2024. Funds: 2.000 €.

NeuroEPI: Mentors in residence. Fundació Bosch i Gimpera de la Universitat de Barcelona. Nº 600431. PI: Christian Griñán Ferré. (Universitat de Barcelona). 30/01/2024- 29/05/2024. Funds: 2.000 €.

Inhibidors de l’epòxid hidrolasa soluble per fer front a la malaltia de Niemman-Pick C (2018 LLAV 00007). Agència de Gestió d’Ajuts Universitaris i de Recerca AGAUR. 2019-2020 PI: Christian Griñán-Ferré. Funds: 20.000,00 €

projects

Contracts

Two extra experimental groups of SAMP8 Horizon IP, S.L. 15/06/2023- 30/12/2024. Funds: 7.560,98 €.
Study of Biosearch Life products on AD-hallmarks by using the Caenorhabditis elegans (C. elegans). 2019. PI: Christian Griñan-Ferré. Funds: 12.623,31€.
Products SDP on aging-hallmarks by using the Caenorhabditis elegans (C. elegans) APC EUROPE, S.A. 2020-2021. PI. Merce Pallas Lliberia; Christian Griñán Ferré. Funds: 15.158,28€.

Patents

Compounds as soluble epoxide hydrolase inhibitors. Gisbert S, Griñán Ferré CG, Pallàs Lliberia M, Vázquez Cruz S. PCT/EP2022/056557. Publication nº: WO/2022/200105. Owner: Universitat de Barcelona. Priority date: 24/03/2021.

Morpholine and 1,4-oxazepane compounds and its use in therapy.Inventors: Griñán-Ferré, CG; Pallàs, M; Bellver, A; Escolano, C; Vázquez, S; Barbaraci. C. PCT/EP2024/067680. Owner: Universitat de Barcelona. Priority date: June 22, 2023.

Secreted splicing variant of klotho for treating bone disorders. Inventors: Roig Soriano, J; Chillón Rodríguez, M; Bosch Merino, A; Pallàs Lliberia, M; Griñán Ferré, CG. PCT/EP2022/063734. Publication nº: WO/2022/243519. Owners: Fundació Institut de Recerca Hospital Universitari Vall d’Hebron, Universitat de Barcelona, Fundació Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona (UAB). Priority date: May 21, 2021.

Dual G9a/GSK-3B inhibitors.Ferré, Christian Gaspar; Bellver Sanchis, Aina; Pallàs Lliberia, Mercè; Ribalta Vilella, Marta; Vázquez Cruz, Santiago; Escolano Mirón, María Carmen; Sánchez Arfelis, Ainoa. 4. April 10, 2024.

Synthetic I₂Imidazoline receptor ligands for prevention or treatment of human brain disorders. Inventors: Escolano MC, Pallàs Lliberia M, Griñán Ferré CG, Abás S, Callado Hernando LF, García Sevilla JA. PCT/EP2018/085742. Owner entities: Universidad del País Vasco / Euskal Herriko Unibertsitatea / Universitat de Barcelona / Universitat de les Illes Balears. Priority date: 21/12/2017.

Methods of treating behavior alterations. Inventors: Maes T, Rotllant Pozo D, Griñán Ferré CG, Pallàs Lliberia M, Nadal Alemany R, Armario García A. PCT/EP2019/071120. Publication nº: WO/2019/025588. Owner: BIOSEARCH, S.A. Priority date: 03/08/2017.

Composition for use in the treatment of cognitive disorders. Inventors: Mónica Olivares Martín, Luis Pérez Martínez, Óscar Bañuelos Hortigüela, José Luís López Larramendi, Mercè Pallàs Lliberia, Cristian Gaspar Griñan Ferre.
PCT/ES2020/070005. Owner: BIOSEARCH, S.A. Priority date: 03/01/2020.

Compounds for use in reducing accumulation of amyloid plaques and/or hyperphosphorylation of tau protein. Inventors: Escolano Mirón MC, Galdeano Cantador C, Griñan Ferre CG, Pallàs Lliberia M, Pujol Bech EA, Vázquez Cruz S. 7. Owner: Universitat de Barcelona. Priority date: April 20, 2018.

Phenoxycyclohexylurea derivatives for use in reducing accumulation of amyloid plaques and/or hyperphosphorylation of tau protein. Inventors: Sandra Codony Gisbert, Cristian Gaspar Griñán Ferré, Rosana Leiva Martínez, Rosana, Mercè Pallàs Lliberia, Santiago Vázquez Cruz. 5. Priority date: April 20, 2018.

Collaborations

Neurotransmission and Neuroreparation Group, led by Dr. José Luis Marco-Contelles, Instituto de Química Orgánica General (IQOG-CSIC), Madrid, Spain.
Nanoparticles and Nanocomposites Group, led by Dr. Anna Laromaine, Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), Barcelona, Spain.
Alzheimer’s and Other Cognitive Disorders Unit, led by Dr. Albert Lladó, Hospital Clínic de Barcelona, Barcelona, Spain.
Memory Unit, Neurology Service, led by Dr. Alberto Lleó, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Molecular Imaging and Therapy Group, led by Dr. Raúl Herance, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain.
MERITT – Etiopathogenesis and Treatment of Severe Mental Disorders Research Group, led by Dr. Núria Tous and Dr. Maria Elena Huerta-Ramos, Parc Sanitari Sant Joan de Déu, Barcelona, Spain.